# BridgeBio Pharma Inc. (BBIO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $74.84, market value $14.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). BridgeBio Pharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 20.5×**. Each dollar of revenue is priced at 20.5×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -3.0%** (5-yr avg -16.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -69.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -146.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: 35.1%**. 35.1% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 60.6%**. Return on all capital, debt included, is 60.6%: comfortably above what that capital costs.
- **Return on assets: -75.0%**. Each dollar of assets produces -75.0% of profit.

## Growth
- **Revenue growth (1 yr): 126.3%** (3-yr 86.3%/yr, 5-yr 127.4%/yr). Revenue grew 126.3% over the last year, against 127.4% a year compounded over five years.
- **EPS growth (1 yr): -31.3%**. Earnings per share fell 31.3%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: net cash**. BridgeBio Pharma Inc. holds more cash than debt.
- **Altman Z-score: -1.52**. A Z-score of -1.52 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. BridgeBio Pharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (21 analysts). 21 analysts cover BridgeBio Pharma Inc.; the consensus is strong_buy, with an average price target of $108.43 (+45% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 44.4%** (YTD -2.2%, 3-mo 10.7%). The shares are up 44.4% over twelve months including dividends.
- **From 52-week high: -19.9%** (53.4% above the low). Trading 20% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 32**. An RSI of 32 is neutral.
- **Beta (1 yr): 1.06** (volatility 47%). Beta of 1.06 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BBIO · Page: https://foliofundamentals.com/stocks/bbio

Not investment advice.